We evaluated baseline CT scans before TACE and 1-month post-TACE to evaluate TACE responses. The treatment response was assessed based on the imaging studies of the patients, which were either 4-phase contrast-enhanced CT scan or dynamic magnetic resonance imaging within 1 month after the initial TACE. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) was used to assess radiological changes of HCC after treatment16 (link). The criteria have four categories; complete response (CR); partial response (PR); stable disease (SD); and progressive disease (PD). Complete or partial response in the imaging study at 1-month post-TACE was classified as TACE response whereas stable or progressive disease was defined as no response. Assessment of tumor response was reviewed independently by two radiologists with expertise in liver imaging to minimize variability. In cases of disagreement, the final decision was obtained by consensus.
TACE Response Evaluation in HCC
We evaluated baseline CT scans before TACE and 1-month post-TACE to evaluate TACE responses. The treatment response was assessed based on the imaging studies of the patients, which were either 4-phase contrast-enhanced CT scan or dynamic magnetic resonance imaging within 1 month after the initial TACE. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) was used to assess radiological changes of HCC after treatment16 (link). The criteria have four categories; complete response (CR); partial response (PR); stable disease (SD); and progressive disease (PD). Complete or partial response in the imaging study at 1-month post-TACE was classified as TACE response whereas stable or progressive disease was defined as no response. Assessment of tumor response was reviewed independently by two radiologists with expertise in liver imaging to minimize variability. In cases of disagreement, the final decision was obtained by consensus.
Corresponding Organization : Prince of Songkla University
Variable analysis
- Amount of iodized oil (range: 4–16 mL)
- Amount of doxorubicin hydrochloride (range: 5–50 mg) or mitomycin-C (range: 10–20 mg) administered via the tumor-feeding hepatic arteries
- TACE response, classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST)
- All patients with HCC were treated using conventional TACE by two experienced interventional radiologists who had at least 10 years of experience
- Procedure was finished when the tumor feeding branch was completely embolized by gelatin sponge particles
- The decision to repeat TACE session was made on demand at an interval of 6–12 weeks in patients with favorable liver function and performance status
- Assessment of tumor response was reviewed independently by two radiologists with expertise in liver imaging to minimize variability
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!